Chiral tripyridine-dipyrrolo-imidazolone ligand, preparation method thereof and application of chiral tripyridine-dipyrrolo-imidazolone ligand in asymmetric catalytic reaction

By designing chiral tripyridine-bispyrroloimidazolone ligand (TPy-BPI), the problem of lack of efficient chiral ligands in asymmetric catalytic synthesis is solved, and the Friedel-Crafts alkylation reaction involved in indole is realized efficient catalytic effect and demonstrate good stability and compatibility.

CN118978540APending Publication Date: 2024-11-19XIANYANG NORMAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411068426.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

In the field of asymmetric catalytic synthesis, there is a lack of efficient, economical and widely applicable advantages of chiral tripyridine ligands, especially in the Friedel-Crafts alkylation reactions involving indole, the stability and compatibility of existing ligands are insufficient. , limiting the progress of drug synthesis.

Method used

A chiral tripyridine-bispyrroloimidazolone ligand (TPy-BPI) was designed and synthesized by the condensation reaction of prolylamide and tripyridine-diformaldehyde. It has electron-rich coordination sites and can be combined with Lewis metals. A five-membered ring coordination is formed for asymmetric catalytic reactions.

Benefits of technology

It realizes the application of chiral ligand in asymmetric catalytic reactions, has good air stability and applicability, is suitable for various substituents, significantly improving the asymmetry of the Friedel-Crafts alkylation reaction involving indole. Catalytic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978540A_ABST
    Figure CN118978540A_ABST
Patent Text Reader

Abstract

The invention discloses a chiral tripyridine-dipyrrolo-imidazolone ligand TPy-BPI (1, 2, 4-triazolo [3, 2-b] imidazolone) and a preparation method thereof. According to the invention, corresponding prolinamide 1 and tripyridine-dicarboxaldehyde 2 are subjected to a condensation reaction, such that a target product chiral tripyridine-dipyrrolo-imidazolone ligand TPy-BPI is generated. The ligand contains a tripyridine group and a pyrrolo-imidazolone group (a nitrogen group of tripyridine and a tertiary amine nitrogen atom of the pyrrolo-imidazolone group belong to electron-rich coordination sites), and can form five-membered ring coordination with Lewis metal, so that a chiral ligand metal compound is generated and is applied as a chiral ligand in an asymmetric catalytic reaction. Therefore, the method has important application value in the field of asymmetric catalytic synthesis, and the synthesis method is very economical, simple and convenient. And the compound also has good air stability and wide applicability, and has good compatibility with various substituent groups.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of chiral chemistry and asymmetric catalytic synthesis, in particular to a chiral tripyridine-bipyrroloimidazole ketone ligand (TPy-BPI) and a preparation method thereof and application thereof in asymmetric catalytic indole-involved Friedel-Crafts alkylation reaction. Background Art

[0002] Chiral pharmaceuticals are at the forefront of the pharmaceutical industry, and the Nobel Prizes in Chemistry in 2001 and 2021 were awarded to the main contributors to chiral catalysis. There are currently about 2,000 drugs in use in the world, of which chiral drugs account for more than 50%. Among the 250 drugs commonly used in clinical practice, there are as many as 200 chiral drugs.

[0003] The key preparation technology of chiral drugs was selected as one of the "Top Ten Chemical Inventions that Changed the World" proposed by IUPAC. Asymmetric catalysis technology is the most efficient and green way to obtain chiral molecules, and one of its core scientific issues is the creation of dominant chiral ligands and catalysts. The design and synthesis of original dominant chiral ligands plays a key role in the development of asymmetric catalytic reactions. It is the most attractive and challenging goal in asymmetric catalysis and can provide core technology for the efficient and green synthesis of chiral drugs and candidate drugs. In addition, economically feasible synthetic routes are also crucial for dominant chiral ligands, so that they can be widely used. In particular, the nitrogen atom of pyridine belongs to the electron-rich coordination site, and the unique properties of the electron pair of terpyridine provide the opportunity to form complexes with a variety of metals. Some research focuses on the development of new chiral tripyridine ligands for metal-catalyzed reactions.

[0004] In this context, we therefore designed and developed a new type of chiral tripyridine-bispyrroloimidazoline ligand (TPy-BPI) and tested their application in the asymmetric Friedel-Crafts alkylation of indoles. Based on the design and synthesis of a new type of chiral tripyridine-bispyrroloimidazoline ligand metal complex, our design ideas refer to the "crab" biomimetic model diagram: the bipyrroloimidazoline group is likened to the two "crab" claws, and the tripyridine group is likened to the "crab" body (such as Figure 1 shown). Summary of the invention

[0005] The purpose of the present invention is to provide a chiral tripyridine-bipyrroloimidazole ketone ligand (TPy-BPI) and a preparation method and application thereof, which is an important class of chiral tripyridine ligands, and the ligands include a tripyridine group and a pyrroloimidazole ketone group (the nitrogen group of the tripyridine and the tertiary amine nitrogen atom of the pyrroloimidazole ketone group belong to electron-rich coordination sites), can form a five-membered ring coordination with a Lewis metal, thereby generating a chiral ligand metal complex, and can be used as a chiral ligand in an asymmetric catalytic reaction. Therefore, it has important application value in the field of asymmetric catalytic synthesis, and its synthesis method is very economical and simple. It also has good air stability, wide applicability, and good compatibility for various substituents.

[0006] The present invention is achieved as follows: a chiral tripyridine-bipyrroloimidazole ligand (TPy-BPI), the compound having a structure as shown in the general formula (I);

[0007]

[0008] In the formula, Ar is a benzene ring substituted with fluorine, chlorine, bromine, ethyl, tert-butyl, isopropyl, methoxy, methyl or hydrogen.

[0009] The method for preparing a chiral tripyridine-bispyrroloimidazolone ligand (TPy-BPI) is characterized in that: a corresponding proline amide 1 undergoes a condensation reaction with a tripyridine-dicarboxaldehyde 2 to generate a target product, a chiral tripyridine-bispyrroloimidazolone ligand TPy-BPI.

[0010] The synthetic route is as follows:

[0011]

[0012] The present invention also finds the application of chiral tripyridine-bipyrroloimidazolone ligand TPy-BPI as a ligand in asymmetric catalytic indole-involved Friedel-Crafts alkylation reaction.

[0013] Our design ideas are:

[0014]

[0015] The mechanism of the Friedel-Crafts alkylation reaction of indole catalyzed by TPy-BPI ligand is as follows:

[0016]

[0017] By adopting the above technical scheme, the corresponding proline amide 1 and the tripyridine-diformaldehyde 2 undergo condensation reaction to generate the final product chiral tripyridine-bipyrroloimidazole ketone ligand TPy-BPI. This type of ligand includes a tripyridine group and a pyrroloimidazole ketone group (the nitrogen group of the tripyridine and the tertiary amine nitrogen atom of the pyrroloimidazole ketone group belong to the electron-rich coordination site), which can form a five-membered ring coordination with a Lewis metal to generate a chiral ligand metal complex, which is used as a chiral ligand in an asymmetric catalytic reaction. Therefore, it has important application value in the field of asymmetric catalytic synthesis, and its synthesis method is very economical and simple. It also has good air stability, wide applicability, and good compatibility for various substituents. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The "crab" bionic model diagram used as a reference in the present invention: the bipyrrolimidazolone group is used as a metaphor for the two "crab" claws, and the tripyridine group is used as a metaphor for the main body of the "crab";

[0019] Figure 2 The design idea and creative diagram of the chiral tripyridine-bipyrroloimidazolidinone ligand TPy-BPI synthesized by the present invention;

[0020] Figure 3 Single crystal images of the chiral ligand TPy-BPI and metal complex synthesized by the present invention;

[0021] Figure 4 This is a single crystal image of the chiral ligand TPy-BPI synthesized by the present invention;

[0022] Figure 5 and Figure 6 The spectral data of the chiral ligand TPy-BPI-1 of the embodiment of the present invention;

[0023] Figure 7 The racemic and chiral liquid phase spectrum data of compound 6a of the embodiment of the present invention; DETAILED DESCRIPTION

[0024] (I) Preparation of chiral tripyridine-bispyrroloimidazolone ligand TPy-BPI

[0025]

[0026] Chiral tripyridine-bipyrroloimidazole ligand TPy-BPI: The raw material proline amide 1a (2.5 eq) and tripyridine-dicarboxaldehyde (1 eq, 0.78 mmol) 2 were dissolved in an appropriate amount of anhydrous ethanol and refluxed for 12 h. After the reaction solution was treated, it was purified by column chromatography to obtain a light yellow solid TPy-BPI-1; melting point: 227.6-228.3 ° C, [α] D 20= +24.1 (c 0.50, CHCl 3 ); yield 82%,>20:1dr; NMR and high resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.83-1.89(m,4H),2.16-2.21(m,4H),2.91-2.97(m,2H),3.42-3.47(m,2H),4.22-4.26(m,2H),5.75(s,2H),6.99-7.02( m,2H),7.17-7.24(m,6H),7.41(d,J=7.6Hz,4H),7.72-7.76(m,2H),7.80-7.84(m,1H),8.30(d,J=7.6Hz,2H),8.43(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:23.9,26.7,55.4,63.9,83.5,119.6,119.7,120.5,120.6,124.2,128. 0,136.6,137.0,137.1,153.4,155.3,156.3,174.4; HRMS(ESI-TOF)m / z:Calcd.for C 39 H 35 N 7 NaO 2 [M+Na] + :656.2741;Found:656.2734.

[0027] The preparation method of the chiral ligands TPy-BPI-2 to TPy-BPI-15 prepared in the examples is the same as that of the chiral ligand TPy-BPI-1, and the feed ratio is the same as that of the ligand TPy-BPI-1, and the ligands TPy-BPI-2 to TPy-BPI-15 can be obtained. The reaction yields are shown in Table 1, but it should be emphasized that the examples are intended to illustrate rather than limit the scope of the present invention. The compounds of the present invention are not limited to the contents shown in Table 1.

[0028] Table 1 shows the chemical structure of the chiral tripyridine-bipyrroloimidazoline ligand TPy-BPI.

[0029]

[0030] This example prepares the chiral ligand TPy-BPI-2: light yellow solid, melting point: 134.1-134.9°C, [α] D 20 =-109.5(c 0.50,CHCl 3); yield 80%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.89-1.94(m,4H),2.09(s,6H),2.17-2.27(m,4H),3.00-3 .06(m,2H),3.42-3.47(m,2H),4.46-4.49(m,2H),5.45(s,2H),6.76(d ,J=7.6Hz,2H),6.94-6.97(m,2H),7.03-7.10(m,4H),7.19(d,J=7.2Hz,2H),7.70-7.78(m,3H),8.14(d,J=8.0Hz,2H),8.45(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:17.0,24.2,27.0,55.6,63.8,84.9,119.6,120.4,120.5,125.7,126.9,127.0,13 0.1,133.8,135.1,136.8,137.0,153.6,155.0,156.5,173.9; HRMS(ESI-TOF)m / z:Calcd.for C 41 H 39 N 7 NaO 2 [M+Na] + :684.3051;Found:684.3053.

[0031] This example prepares the chiral ligand TPy-BPI-3: light yellow solid, melting point: 124.6-125.2°C, [α] D 20 =-93.0(c 0.50,CHCl 3 ); yield 77%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3,400MHz)δ:1.84-1.92(m,4H),2.15-2.23(m,4H),3.02-3.08(m,2H),3.41-3.46(m,2H),4.31-4.34(m,2H),5.72(s,2H),6.88-6.9 2(m,2H),6.98-7.09(m,4H),7.16-7.25(m,4H),7.68-7.72(m,2H),7.77-7.81(m,1H),8.18(d,J=7.6Hz,2H),8.40(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:24.0,26.8,55.4,63.2,83.6,115.2(d,J CF =20.1Hz),119.5,120.3(d,J CF =4.4Hz),123.2(d,J CF =11.0Hz),123.5,127.5(d,J CF =8.3Hz),128.2,136.9,137.0,153.6,154.9,156.0,156.8(d,J CF =248.2Hz),174.8; HRMS(ESI-TOF)m / z:Calcd.forC 39 H 33 F 2 N 7 NaO 2 [M+Na] + :692.2556;Found:692.2559.

[0032] This example prepares the chiral ligand TPy-BPI-4: light yellow solid, melting point: 139.3-139.9°C, [α] D 20 = +12.2 (c 0.50, CHCl 3 ); yield 81%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3,400MHz)δ:1.82-1.88(m,4H),2.15(s,6H),2.16-2.20(m,4H),2.90-2 .96(m,2H),3.41-3.46(m,2H),4.22-4.25(m,2H),5.70(s,2H),6.97(d ,J=8.4Hz,4H),7.18-7.21(m,2H),7.27(d,J=8.4Hz,4H),7.70-7.74(m,2H),7.80-7.84(m,1H),8.31(d,J=8.0Hz,2H),8.42(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:19.8,23.9,26.7,55.4,63.9,83.7,119.5,119.7,120.5,120.8,128.5,13 3.9,134.0,137.0,137.1,153.7,155.3,156.4,174.2; HRMS(ESI-TOF)m / z:Calcd.for C 41 H 39 N 7 NaO 2 [M+Na] + :684.3051;Found:684.3037.

[0033] This example prepares the chiral ligand TPy-BPI-5: light yellow solid, melting point: 135.9-136.6°C, [α] D 20 = +11.3 (c 0.50, CHCl 3 ); yield 80%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.81-1.89(m,4H),2.15-2.21(m,4H),2.90-2.96(m,2H),3.41-3.46(m,2H),4.23-4.26(m,2H),5.68(s,2H),6.85-6.8 9(m,4H),7.19-7.23(m,2H),7.34-7.37(m,4H),7.72-7.76(m,2H),7.81-7.85(m,1H),8.28(d,J=7.6Hz,2H),8.44(d,J=7.6Hz,2H); 13 C NMR (CDCl 3,100MHz)δ:23.9,26.7,55.4,63.8,83.9,114.7(d,J CF =22.3Hz),119.7(d,J CF =18.4Hz),120.5,122.8(d,J CF =8.1Hz),132.5,132.6,137.1,137.2,153.6,155.2,156.0,158.8(d,J CF =244.4Hz),174.3; HRMS(ESI-TOF)m / z:Calcd.for C 39 H 33 F 2 N 7 NaO 2 [M+Na] + :692.2556;Found:692.2548.

[0034] This example prepares the chiral ligand TPy-BPI-6: light yellow solid, melting point: 145.7-146.4°C, [α] D 20 = +2.6 (c 0.50, CHCl 3 ); yield 82%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.81-1.86(m,4H),2.13-2.19(m,4H),2.86-2.92(m,2H),3.40-3.45(m,2H),4.19-4.21(m,2H),5.72 (s,2H),7.21-7.35(m,10H),7.72-7.76(m,2H),7.79-7.82(m,1H),8.22(d,J=7.6Hz,2H),8.43(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:23.9,26.7,55.4,63.8,83.2,117.0,119.7,119.8,120.5,121.9,130. 9,135.8,137.0,137.2,153.6,155.2,155.8,174.4; HRMS(ESI-TOF)m / z:Calcd.for C 39 H 34 Br 2 N 7 O 2 [M+H]+ :790.1121;Found:790.1104.

[0035] This example prepares the chiral ligand TPy-BPI-7: light yellow solid, melting point: 137.5-138.4°C, [α] D 20 = +33.5 (c 0.50, CHCl 3 ); yield 80%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.81-1.87(m,4H),2.14-2.20(m,4H),2.86-2.92(m,2H),3.41-3.45(m,2H),4.20-4.22(m,2H),5.74(s,2H),6. 99-7.03(m,2H),7.11(d,J=8.0Hz,2H),7.25-7.30(m,4H),7.74-7.84(m,5H),8.25(d,J=7.6Hz,2H),8.44(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:23.9,26.7,55.4,63.8,83.1,118.5,119.7,119.8,120.5,121.6,123.2,127.0 ,129.2,137.1,137.3,138.0,153.6,155.2,155.8,174.5; HRMS(ESI-TOF)m / z:Calcd.forC 39 H 34 Br 2 N 7 O 2 [M+H] + :790.1121;Found:790.1114.

[0036] This example prepares the chiral ligand TPy-BPI-8: light yellow solid, melting point: 147.2-148.3°C; yield 75%, >20:1dr; nuclear magnetic resonance and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3,400MHz)δ:1.82-1.87(m,2H),1.92-1.98(m,2H),2.17-2.25(m,4H),3.19- 3.25(m,2H),3.41-3.46(m,2H),4.40-4.43(m,2H),5.75(s,2H),6.91-6.99( m,4H),7.05-7.10(m,2H),7.20(d,J=7.6Hz,2H),7.32-7.35(m,2H),7.69-7 .73(m,2H),7.81-7.85(m,1H),8.23(d,J=8.0Hz,2H),8.47(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:24.1,27.1,55.4,63.4,83.4,119.5,120.3,120.7,126.7,128.0,129.1,129. 9,131.2,132.6,137.0,137.2,153.6,154.9,156.0,175.0; HRMS(ESI-TOF)m / z:Calcd.for C 39 H 34 Cl 2 N 7 O 2 [M+H] + :702.2146;Found:702.2151.

[0037] This example prepares the chiral ligand TPy-BPI-9: light yellow solid, melting point: 125.3-126.3°C, [α] D 20 = +35.0 (c 0.50, CHCl 3 ); yield 77%,>20:1dr; NMR and high resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.82-1.88(m,4H),2.15-2.21(m,4H),2.87-2.93(m,2H),3.41-3.46(m,2H),4.21-4.23(m,2H),5.74(s,2H),6.96-6.9 8(m,2H),7.06-7.10(m,2H),7.24-7.27(m,4H),7.64-7.65(m,2H),7.75-7.84(m,3H),8.26(d,J=8.0Hz,2H),8.45(d,J=8.0Hz,2H); 13 C NMR (CDCl3 ,100MHz)δ:23.9,26.7,55.4,63.8,83.1,118.0,119.7,120.3,120.5,124.0,128.9,1 33.6,137.1,137.3,137.9,153.6,155.2,155.8,174.5; HRMS(ESI-TOF)m / z:Calcd.for C 39 H 34 Cl 2 N 7 O 2 [M+H] + :702.2146;Found:702.2148.

[0038] This example prepares the chiral ligand TPy-BPI-10: light yellow solid, melting point: 144.7-145.5°C, [α] D 20 = +12.2 (c 0.50, CHCl 3 ); yield 77%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.83-1.88(m,4H),2.15-2.21(m,4H),2.88-2.95(m,2H),3.41-3.46(m,2H),4.19-4.23(m,2H),5.72(s,2H),7.12-7. 16(m,4H),7.22-7.24(m,2H),7.37-7.41(m,4H),7.73-7.77(m,2H),7.80-7.84(m,1H),8.25(d,J=8.0Hz,2H),8.43-8.45(m,2H); 13 CNMR (CDCl 3 ,100MHz)δ:23.9,26.7,55.4,63.8,83.3,119.7,119.8,120.5,121.6,128.0,129.3 ,135.2,137.0,137.2,153.6,155.2,155.9,174.4; HRMS(ESI-TOF)m / z:Calcd.forC 39 H 34 Cl 2 N 7 O 2 [M+H] + :702.2146;Found:702.2143.

[0039] This example prepares the chiral ligand TPy-BPI-11: light yellow solid, melting point: 139.4-140.5°C, [α] D 20 = +11.9 (c 0.50, CHCl 3 ); yield 80%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.04-1.08(m,6H),1.82-1.88(m,4H),2.15-2.20(m,4H),2.43-2. 49(m,4H),2.90-2.96(m,2H),3.40-3.45(m,2H),4.22-4.25(m,2H),5.71(s,2 H),7.00(d,J=8.4Hz,4H),7.21(d,J=7.6Hz,2H),7.30(d,J=8.4Hz,4H),7.71- 7.74(m,2H),7.79-7.83(m,1H),8.30(d,J=8.0Hz,2H),8.42(d,J=8.0Hz,2H); 13 C NMR (CDCl 3 ,100MHz)δ:14.4,23.9,26.7,27.2,55.4,63.8,83.7,119.5,119.7,120.5,120.8,127.3 ,134.1,136.9,137.1,140.3,153.7,155.2,156.4,174.2; HRMS(ESI-TOF)m / z:Calcd.for C 43 H 43 N 7 NaO 2 [M+H] + :712.3370;Found:712.3370.

[0040] This example prepares the chiral ligand TPy-BPI-12: light yellow solid, melting point: 167.7-168.3°C, [α] D 20 =-18.9(c 0.50,CHCl 3 ); yield 83%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3,400MHz)δ:1.83-1.87(m,4H),2.15-2.21(m,4H),2.91-2.98(m,2H),3.40-3.45(m,2H),4.25-4.28(m,2H),5.65(s,2H),6.70(d,J =7.2Hz,4H),7.19-7.21(m,2H),7.24-7.27(m,4H),7.71-7.74(m,2H),7.81-7.85(m,1H),8.32(d,J=8.0Hz,2H),8.43-8.45(m,2H); 13 CNMR (CDCl 3 ,100MHz)δ:23.9,6.7,54.3,55.5,63.8,84.2,113.2,119.5,119.9,120.5,123.1,12 9.3,137.0,137.1,153.7,155.2,156.2,156.4,174.1; HRMS(ESI-TOF)m / z:Calcd.for C 41 H 39 N 7 NaO 4 [M+H] + :716.2956;Found:716.2963.

[0041] This example prepares the chiral ligand TPy-BPI-13: light yellow solid, melting point: 268.1-269.2°C, [α] D 20 = +16.3 (c 0.50, CHCl 3 ); yield 82%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.07(s,6H),1.09(s,6H),1.82-1.88(m,4H),2.15-2.21(m,4H),2 .69-2.76(m,2H),2.90-2.96(m,2H),3.41-3.46(m,2H),4.22-4.25(m,2H),5. 71(s,2H),7.04(d,J=8.8Hz,4H),7.23-7.25(m,2H),7.30(d,J=8.4Hz,4H),7. 72-7.76(m,2H),7.79-7.83(m,1H),8.29(d,J=8.0Hz,2H),8.43-8.45(m,2H); 13 C NMR (CDCl 3,100MHz)δ:22.9,23.9,26.7,32.5,55.4,63.8,83.7,119.5,119.7,120.5,120.7,125.9 ,134.2,137.0,137.1,144.9,153.7,155.2,156.4,174.2; HRMS(ESI-TOF)m / z:Calcd.for C 45 H 48 N 7 O 2 [M+H] + :718.3857;Found:718.3849.

[0042] This example prepares the chiral ligand TPy-BPI-14: light yellow solid, melting point: 273.4-274.4°C, [α] D 20 = +12.5 (c 0.50, CHCl 3 ); yield 83%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR (CDCl 3 ,400MHz)δ:1.15(s,18H),1.82-1.88(m,4H),2.15-2.21(m,4H),2.89-2.95(m,2H),3.41-3.46(m,2H),4.22-4.25(m, 2H),5.72(s,2H),7.18-7.26(m,6H),7.30-7.33(m,4H),7.73-7.82(m,3H),8.29(d,J=7.6Hz,2H),8.43-8.45(m,2H); 13 C NMR (CDCl 3 ,100MHz)δ:23.9,26.7,30.2,33.3,55.4,63.8,83.6,119.5,119.6,120.3,120.5,124.8 ,133.9,137.0,137.1,147.1,153.7,155.3,156.4,174.2; HRMS(ESI-TOF)m / z:Calcd.for C 47 H 52 N 7 O 2 [M+H] + :746.4175;Found:746.4168.

[0043] This example prepares the chiral ligand TPy-BPI-15: light yellow solid, melting point: 135.6-136.2°C, [α]D 20 =-155.6(c 0.50,CHCl 3 ); yield 70%,>20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR (CDCl 3 ,400MHz)δ:1.83-1.90(m,2H),1.97-2.01(m,2H),2.20-2.26(m,4H),3.27 -3.33(m,2H),3.40-3.46(m,2H),4.42-4.46(m,2H),5.78(s,2H),6.85-6. 87(m,2H),6.98-7.03(m,4H),7.18-7.20(m,2H),7.51-7.53(m,2H),7.69- 7.73(m,2H),7.82-7.86(m,1H),8.24(d,J=8.0Hz,2H),8.45-8.47(m,2H); 13 C NMR (CDCl 3 ,100MHz)δ:24.2,27.2,55.5,63.5,83.5,119.6,120.4,120.8,121.4,127.4,128.4,130. 3,132.3,134.1,137.0,137.3,153.6,155.0,156.0,175.0; HRMS(ESI-TOF)m / z:Calcd.for C 39 H 34 Br 2 N 7 O 2 [M+H] + :790.1121;Found:790.1132.

[0044] (II) Application of Chiral Tripyridine-Bispyrroloimidazolone Ligand TPy-BPI in Asymmetric Catalytic Friedel-Crafts Alkylation of Indoles

[0045] The chiral tripyridine-bipyrroloimidazolone ligand TPy-BPI of formula (1) of the present invention comprises a tripyridine group and a pyrroloimidazolone group (the nitrogen group of the tripyridine and the tertiary amine nitrogen atom of the pyrroloimidazolone group belong to electron-rich coordination sites), which can form a five-membered ring coordination with a Lewis metal to generate a chiral ligand metal complex, and is used as a dominant chiral ligand in asymmetric catalytic Friedel-Crafts alkylation reaction involving indole. However, it should be emphasized that the chiral ligand TPy-BPI of the present invention is not limited to being used as a chiral ligand in asymmetric catalytic Friedel-Crafts alkylation reaction of indole.

[0046] Example 1: Application of chiral ligand TPy-BPI with various substituents in asymmetric catalytic reactions

[0047] In order to demonstrate the application value of the developed chiral ligand TPy-BPI in asymmetric catalytic systems, we selected the Friedel-Crafts alkylation reaction of indole 4a and enone lactam 5a as the template reaction, and selected compounds TPy-BPI-1 to TPy-BPI-15 as chiral ligands to react with Lewis acid Ni(OTf) 2 The chiral complex was generated in situ to verify the asymmetric catalytic effect of the chiral ligand TPy-BPI (Table 2).

[0048] Table 2 shows the application of chiral ligand TPy-BPI with various substituents in asymmetric catalytic reactions

[0049]

[0050] Experimental conclusion: The asymmetric catalytic Friedel-Crafts alkylation template reaction of indole 4a and enone lactam 5a was selected as the evaluation index. The experimental results show that the chiral ligands TPy-BPI-1 to TPy-BPI-15 with various substituents shown in formula (1) all show asymmetric catalytic effects in the Friedel-Crafts alkylation reaction of indole 4a and enone lactam 5a, and can be developed into a new advantageous chiral tripyridine-bipyrroloimidazole ligand TPy-BPI, which is worthy of further in-depth study.

[0051] Example 2: Application of chiral ligand TPy-BPI-1 in asymmetric catalytic reactions

[0052] In order to demonstrate the application value of the developed chiral ligand TPy-BPI-1 in asymmetric catalytic systems, we selected the Friedel-Crafts alkylation reaction of various substituted indoles 4 and various substituted enone lactams 5 as the template reaction to verify the catalytic effect of the chiral ligand TPy-BPI-1 (Table 3).

[0053] Table 3 shows the application of chiral ligand TPy-BPI-1 in asymmetric catalytic reactions

[0054]

[0055] Experimental conclusion: The Friedel-Crafts alkylation template reaction of various substituted indoles 4 and various substituted enone lactams 5 was selected as the evaluation index. The experimental results show that the chiral ligand TPy-BPI represented by formula (1) has good affinity with Ni(OTf) 2 The in situ generated chiral complex showed asymmetric catalytic effect in the Friedel-Crafts alkylation reaction of indoles 4 with various substituents and enone lactams 5 with various substituents, and can be developed into a new advantageous chiral ligand TPy-BPI, which is worthy of further in-depth study.

Claims

1. A chiral tripyridine-bispyrroloimidazole ligand TPy-BPI, characterized in that: The compound has a structure as shown in general formula (I); In the formula, Ar is a benzene ring substituted with fluorine, chlorine, bromine, ethyl, tert-butyl, isopropyl, methoxy, methyl or hydrogen; Among them, the chiral tripyridine-bipyrroloimidazole ligand TPy-BPI is specifically one of the following structural formulas:

2. A method for preparing the chiral tripyridine-bipyrroloimidazolone ligand TPy-BPI as claimed in claim 1, characterized in that: The corresponding proline amide 1 undergoes a condensation reaction with tripyridine-dicarboxaldehyde 2 to generate the target product, a chiral tripyridine-bipyrroloimidazole ligand TPy-BPI; The synthetic route is as follows:

3. A use of the chiral tripyridine-bispyrroloimidazolone ligand TPy-BPI as claimed in claim 1 as a ligand in asymmetric catalytic Friedel-Crafts alkylation reaction involving indole.